NMDA receptor dependent anti-diabetic effects

We generated mice with a pancreas-specific deletion of all NMDA receptors. The phenotype of these mice and their pancreatic islets were characterized in terms of insulin secretion, glucose tolerance and calcium oscillations. We also pharmacologically inhibited the NMDA receptors in vitro and in vivo. Subsequently, insulin secretion from isolated mouse and human islets as well as blood glucose and plasma insulin concentrations were analyzed in mice and via a clinical trial in type 2 diabetic patients. Functional NMDA receptors are expressed in insulin producing cells. A pancreas specific NMDA receptor knockout selectively increases glucose stimulated insulin secretion in vitro and improves glucose tolerance in vivo. The pharmacological inhibition of NMDA receptors selectively increases glucose stimulated insulin secretion in vitro and improves glucose tolerance in C57Bl/6 and diabetic mice. In addition, we performed a clinical trial in patients with type 2 diabetes and provided evidence that the NMDA receptor antagonist Dextromethorphan (DXM) lowers blood glucose levels and increases insulin secretion without the risk of hypoglycemia. We show for the first time that NMDA receptors can be targeted genetically and pharmacologically in mice and men to selectively increase glucose stimulated insulin secretion with improvement of glucose tolerance. We uncovered a new role for NMDA receptors in the pancreas and showed that inhibiting these receptors might serve as a useful treatment of human diabetes in pediatric and adult patients.